Freitag, 09.10.2020 23:45 von PR Newswire | Aufrufe: 249

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AMAG Pharmaceuticals, Inc. - AMAG

Der Test einer Laborprobe. (Symbolbild) © alvarez / E+ / Getty Images http://www.gettyimages.de

PR Newswire


NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (AMAG) relating to its acquisition by Covis Group S.à.r.l. Under the terms of the agreement, AMAG shareholders shall be entitled to receive $13.75 in cash for each share of AMAG common stock owned.

The investigation focuses on whether AMAG and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process and  2) whether and by how much this proposed transaction undervalues the Company.

Click here for more information: https://www.monteverdelaw.com/case/american-renal-associates-holdings-inc. It is free and there is no cost or obligation to you.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions.  Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in AMAG Pharmaceuticals, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Kurse

  

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guAMAGntee a similar outcome with respect to any future matter.

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guAMAGntee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-amag-pharmaceuticals-inc--amag-301149697.html

SOURCE Monteverde & Associates PC

Werbung
Mehr Nachrichten Steinhoff Aktie kostenlos abonnieren
E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptieren Sie die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.

Andere Nutzer interessierte auch dieser Artikel: